GET DAILY SIGNALSStryker (SYK) Delivers 7.7% Sales Growth in Q3 but Lowers Full-Year Outlook
Key Takeaways
- Stryker reported third quarter 2026 net sales of $6.52 billion, up 7.7% year over year, but below the analyst consensus of roughly $6.62 billion.
- Adjusted EPS came in at $3.52, up 10.3% from a year ago, narrowly missing the $3.55 consensus estimate.
- Reported GAAP diluted EPS fell 11.7% to $1.96, pressured by higher expenses and special charges.
- Management lowered its full-year 2026 outlook, citing softer hip and knee procedure trends and lingering supply constraints.
- MedSurg and Neurotechnology sales grew 9.2%, while the Orthopaedics segment rose a more modest 5.7%.
- Shares slid about 7.6% in after-hours trading following the release.
Earnings Context and Why It Matters
Stryker stands as one of the largest medical technology companies globally, holding leading positions in orthopedics, medical and surgical equipment, and neurotechnology. Its quarterly results offer a useful gauge of elective procedure demand, hospital capital spending, and overall healthcare activity. The third quarter of 2026 held particular interest given the company’s earlier cyberattack and systems rollout in its orthopedics businesses. I also checked this using Tickeron’s AI Screener to see how SYK compares with peers in the space. Investors were looking to see if robust capital-equipment demand could counter softer trends in joint replacements. The results, along with the reduced full-year guidance, point to how procedure volumes and affordability issues are influencing the medical device sector as we head into 2027.
Reported Results
For the quarter ended September 30, 2026, SYK posted net sales of $6.52 billion, a 7.7% rise from $6.06 billion a year earlier. Organic sales growth also reached 7.7%. The figure landed below the roughly $6.62 billion consensus. Reported net earnings declined 12.3% to $753 million, producing diluted EPS of $1.96 versus $2.22 previously. Adjusted EPS, which excludes one-time items, rose 10.3% to $3.52 and came in just under the $3.55 analyst target. Segment performance showed MedSurg and Neurotechnology advancing 9.2%, while Orthopaedics increased 5.7%. Adjusted operating margin expanded 60 basis points to 26.2%, though the reported margin slipped to 15.9% from 18.7%. Management trimmed its full-year outlook to organic sales growth of 6.5% to 7% and adjusted EPS of $14.80 to $14.90.
Market Reaction and Investor Sentiment
The market responded negatively to the revenue and EPS shortfalls combined with the lowered guidance. SYK shares dropped roughly 7.6% in after-hours trading to around $288. The reaction reflected disappointment in both the headline numbers and management’s comments on slowing hip and knee procedures, with CEO Kevin Lobo noting that results “fell short of our expectations.” While adjusted earnings growth and margin improvement showed operational strength, the softer demand outlook carried more weight for investors.
Forward Outlook and Key Factors to Monitor
Going forward, attention will center on whether the softer hip and knee procedure environment stabilizes. Management linked the slowdown to affordability pressures from higher insurance premiums and deductibles, plus more pre-authorization denials. Supply normalization in the peripheral vascular business remains another focus, with a full recovery expected by year-end. The company is also working to improve execution around its Mako robotics platform and new product launches after earlier disruptions. On a more positive note, capital-equipment demand stays strong, with a solid order book and double-digit growth in areas such as Endoscopy and OrthoTech. SYK repurchased $1 billion of shares in the quarter and gained authorization for another $3 billion. Management anticipates solid fourth-quarter results and momentum into 2027, though formal guidance will come early next year. Procedure trends, supply recovery, and margin execution will stay the main items to watch.
Using AI Tools to Track Medical Device Stocks
In my ongoing review of names like SYK, I find Tickeron’s AI Screener helpful for quickly comparing fundamentals, technical patterns, and peer performance across the medical device sector. It surfaces relevant ideas without requiring hours of manual work and helps keep my watchlist focused on the factors that matter most after earnings releases.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for SYK turns positive, indicating new upward trend
SYK saw its Momentum Indicator move above the 0 level on October 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In 55 of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at 61%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for SYK just turned positive on September 28, 2026. Looking at past instances where SYK's MACD turned positive, the stock continued to rise in 23 of 44 cases over the following month. The odds of a continued upward trend are 52%.
SYK moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SYK crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +3.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYK advanced for three days, in 171 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 128 of 258 cases where SYK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.
Bearish Trend Analysis
The 10-day RSI Indicator for SYK moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 22 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 58%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
SYK broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. SYK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.861) is normal, around the industry mean (3.824). P/E Ratio (31.244) is within average values for comparable stocks, (1.677). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (11.052). Dividend Yield (0.012) settles around the average of (0.010) among similar stocks. P/S Ratio (4.259) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of reconstructive, medical and surgical, and neurotechnology and spine products
Industry MedicalNursingServices
Advertisement